BrainsWay Ltd. (NASDAQ:BWAY) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bob Yedid – LifeSci Advisors Chris von Jako – President and Chief Executive Officer Scott Areglado – Chief Financial Officer Conference Call Participants Jeffery Cohen – Ladenburg Thalmann Jayson Bedford – Raymond James Steven Lichtman – Oppenheimer Jason Wittes – Loop Capital Carl Byrnes – Northland Capital Markets Operator Greetings, and welcome to BrainsWay First Quarter 2022 Earnings Conference Cal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...

BrainsWay Ltd. (NASDAQ:BWAY) Q4 2021 Earnings Conference Call March 9, 2022 8:30 AM ET Company Participants Bob Yedid – Managing Director-LifeSci Advisors, LLC Christopher von Jako – President and Chief Executive Officer Scott Areglado – Chief Financial Officer Conference Call Participants Jeffery Cohen – Ladenburg Thalmann Jayson Bedford – Raymond James Jason Witz – Loop Capital Carl Byrnes – Northland Capital Steven Lichtman – Oppenheimer & Co. Boobalan Pachaiyappan – H.C. Wainwright Operator Greetings, a ...

[Financial and Operational Highlights](index=1&type=section&id=Recent%20Financial%20and%20Operational%20Highlights) BrainsWay reported strong 2021 financial and operational growth, including **34%** revenue increase and **20%** Deep TMS installed base expansion Full-Year 2021 Key Metrics | Metric | Value | Change vs 2020 | | :--- | :--- | :--- | | Full-Year Revenue | $29.7 million | +34% | | Q4 Revenue | $8.5 million | +20% | | Total Deep TMS Installed Base | 754 systems | +20% | | Cash and Equivalents (as of Dec 31, 2021) | $57.3 million | N/A | - Achieved final Local Coverage Determination (LCD) from a Medicare Administrative Contractor (Palmetto GBA MAC), providing Deep TMS™ coverage for OCD treatment to over **9 million** patients. This brings the total number of covered lives for OCD to approximately **60 million**[3](index=3&type=chunk)[5](index=5&type=chunk) - As of year-end 2021, the company had shipped **302** OCD coils as add-on helmets for its Deep TMS systems[3](index=3&type=chunk) - The company has demonstrated year-over-year revenue growth for **six** consecutive quarters, despite challenges from the Omicron surge[4](index=4&type=chunk) [Financial Results](index=2&type=section&id=Financial%20Results) Revenue grew in Q4 and full-year 2021, but increased operating expenses led to higher losses, while an equity offering significantly strengthened cash [Fourth Quarter 2021 Financial Results](index=2&type=section&id=Fourth%20Quarter%202021%20Financial%20Results) Q4 2021 revenue increased **20%** to **$8.5 million** with stable gross margin, but operating expenses rose, leading to a higher operating loss Q4 2021 vs Q4 2020 Financials | Metric | Q4 2021 | Q4 2020 | | :--- | :--- | :--- | | Total Revenues | $8.5 million | $7.1 million | | Gross Margin | 77% | 77% | | Operating Expenses | $8.0 million | $5.9 million | | Operating Loss | $1.5 million | $0.4 million | [Full-Year 2021 Financial Results](index=2&type=section&id=Financial%20Results%20for%20the%20Full-Year%20Ended%20December%2031%2C%202021) Full-year 2021 revenue grew **34%** to **$29.7 million**, with positive cash from operations, despite a widened net loss, and a **$57.3 million** cash balance from an equity offering Full-Year 2021 vs 2020 Financials | Metric | FY 2021 | FY 2020 | | :--- | :--- | :--- | | Total Revenue | $29.7 million | $22.1 million | | Cash from Operations | $0.9 million | ($1.4 million) | | Net Loss | $6.5 million | $5.4 million | | Cash & Equivalents (Year-End) | $57.3 million | $17.2 million | [Financial Statements](index=5&type=section&id=Financial%20Statements) Financial statements reflect increased assets and equity from an offering, strong revenue growth offset by higher expenses leading to a larger net loss, and positive cash from operations [Consolidated Statements of Financial Position](index=5&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20FINANCIAL%20POSITION) Total assets more than doubled to **$75.7 million** by year-end 2021, driven by increased cash and a substantial rise in total equity to **$57.3 million** due to an equity offering Balance Sheet Highlights (in thousands USD) | Account | Dec 31, 2021 | Dec 31, 2020 | | :--- | :--- | :--- | | **Total Assets** | **$75,732** | **$34,011** | | Cash, cash equivalents & short-term deposits | $57,349 | $17,182 | | **Total Liabilities** | **$18,408** | **$14,377** | | **Total Equity** | **$57,324** | **$19,634** | [Consolidated Statements of Comprehensive Loss](index=6&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20COMPREHENSIVE%20LOSS) Full-year 2021 revenue increased **34%** to **$29.7 million**, but rising operating expenses led to a widened net loss of **$6.5 million**, or **($0.21)** per share Income Statement Summary (in thousands USD, except per share data) | Metric | Full-Year 2021 | Full-Year 2020 | Q4 2021 | Q4 2020 | | :--- | :--- | :--- | :--- | :--- | | Revenues | $29,657 | $22,057 | $8,470 | $7,066 | | Gross Profit | $23,058 | $16,999 | $6,564 | $5,500 | | Operating Loss | ($4,999) | ($4,829) | ($1,452) | ($407) | | Net Loss | ($6,462) | ($5,385) | ($1,347) | ($406) | | Basic and Diluted Net Loss per Share | ($0.21) | ($0.24) | ($0.04) | ($0.02) | [Consolidated Statements of Cash Flows](index=7&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) In 2021, cash from operations turned positive at **$0.9 million**, while investing activities used **$42.2 million**, and financing activities provided **$41.5 million** from a share issuance Cash Flow Summary (in thousands USD) | Cash Flow Activity | Full-Year 2021 | Full-Year 2020 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $884 | ($1,436) | | Net cash used in investing activities | ($42,216) | ($2,465) | | Net cash provided by (used in) financing activities | $41,516 | ($1,030) | | **Cash and cash equivalents at end of year** | **$16,921** | **$16,961** | [Company Overview and Forward-Looking Statements](index=3&type=section&id=About%20BrainsWay) BrainsWay, a leader in Deep TMS™, holds three FDA-cleared indications, but faces future risks including market acceptance, regulatory approvals, competition, and reimbursement challenges - BrainsWay is the only TMS company with **three** FDA-cleared indications backed by pivotal studies: major depressive disorder (including anxious depression), obsessive-compulsive disorder, and smoking addiction[11](index=11&type=chunk) - The company is conducting additional clinical trials to expand the use of Deep TMS for other psychiatric, neurological, and addiction disorders[11](index=11&type=chunk) - Key risks include changes in technology, delays in clinical trials, failure to obtain regulatory approvals, competition, and inadequate reimbursement from third-party payers[12](index=12&type=chunk) [Conference Call and Webcast Information](index=2&type=section&id=Conference%20Call%20and%20Webcast) BrainsWay management will host a conference call and webcast on **Wednesday, March 9, 2022, at 8:30 AM Eastern Time**, to discuss Q4 and full-year 2021 results - Event: Discussion of Q4 and Full-Year 2021 Results[8](index=8&type=chunk) - Date and Time: **Wednesday, March 9, 2022, at 8:30 AM Eastern Time**[8](index=8&type=chunk)[9](index=9&type=chunk) - Access: Available via webcast at the company's investor relations website or by phone using Conference ID **13727217**[9](index=9&type=chunk)[10](index=10&type=chunk)

BrainsWay Ltd. (NASDAQ:BWAY) Q3 2021 Earnings Conference Call November 17, 2021 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors, IR Christopher von Jako - President and CEO Scott Areglado - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer Destiny Hance - Ladenburg Thalmann Jayson Bedford - Raymond James Boobalan Pachaiyappan - H.C. Wainwright Operator Greetings and welcome to the BrainsWay Third Quarter 2021 Earnings Conference Call. At this time, all participa ...

Elevating Mental Health Treatments November 2021 Nasdaq/TASE: BWAY Disclaimer Safe Harbor and Non-GAAP Financial Measures This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire any of the Company's securities or to participate in any investment in the Company. No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters containe ...

Exhibit 99.1 BRAINSWAY LTD. 19 Hartum Street, Bynet Building, 3rd Floor Har HaHotzvim, Jerusalem 9777518 Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on December 22, 2021 The Annual General Meeting of Shareholders of BrainsWay Ltd. (the "Company"), will be held at the offices of the Company, 19 Hartum Street, Bynet Building, 3rd Fl, Har HaHotzvim, Jerusalem, Israel on December 22, 2021 at 3:00 p.m. Israel time, or at any adjournments thereof (the "Annual Meeting"), for the following pu ...

Elevating Mental Health Treatments Christopher von Jako, PhD September 2021 Nasdaq/TASE: BWAY Disclaimer Safe Harbor and Non-GAAP Financial Measures This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire any of the Company's securities or to participate in any investment in the Company. No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessm ...

BrainsWay Ltd. (NASDAQ:BWAY) Q2 2021 Earnings Conference Call August 11, 2021 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors, IR Christopher von Jako - President and CEO Scott Areglado - Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Steven Lichtman - Oppenheimer Jeffrey Cohen - Ladenburg Thalmann Jason Wittes - Northland Ram Selvaraju - H.C. Wainwright Operator Greetings. Welcome to the BrainsWay Second Quarter 2021 Earnings Conference Call. At this ti ...

Boldly Advancing Neuroscience August 2021 Nasdaq/TASE: BWAY Disclaimer Safe Harbor and Non-GAAP Financial Measures This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire any of the Company's securities or to participate in any investment in the Company. No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters contained herei ...